Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI [total body irradiation] Followed By Donor Stem Cell Transplantation [with cyclosporine and mycophenolate mofetil] For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome.

Trial Profile

Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI [total body irradiation] Followed By Donor Stem Cell Transplantation [with cyclosporine and mycophenolate mofetil] For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Fludarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Ciclosporin; Methotrexate; Mycophenolate mofetil
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2009 Planned number of patients changed from 20 to 40 and actual end date (Jul 2002) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top